您当前的位置 : 英语  >  investment
Investment Industries——Bio-medicine industry
2017-01-06 18:29:00 editor:王宁
  

  1. Development priorities

  The Binhai New Area focuses on developing three major fields of modern bio-pharmaceuticals, new chemical pharmaceuticals and modern Chinese medicine. Among which, in the field of bio-pharmaceuticals, the New Area focuses on developing bio-engineering drugs, biological chips for gene detection, biological enzyme preparations, various types of vaccines and in vitro diagnostic reagents and other products to accelerate the pace of industrialization. In the field of new chemical pharmaceuticals, it focuses on the development of crude drug and preparation integration, consolidates the advantage of hormones, antibiotics, vitamins and amino acids , build the drug production base for treating cardiovascular and cerebrovascular, diabetes, cancer and other major diseases, improve preparations and accelerate new drug R&D. In the field of modern Chinese medicine, it focuses on developing the technology of secondary development of new Chinese medicine and Chinese patent medicine, accelerates the development of new preparations such as transdermal absorption, targeted therapy and targeted therapy, carries out the research and application of the technology and standard of modern Chinese medicine testing and conducts R&D of Chinese veterinary drug to keep the domestic leading position of modern Chinese medicine. The New Area develops and expands the cluster of medicine R&D service outsourcing industry, focuses on bio-pharmaceutical research and development in line with international standards and promotes industry-university-research cooperation in the field of traditional Chinese medicine. It also vigorously develops R&D and manufacturing of high-end digital medical imaging equipment, diagnostic reagents, detection equipment, interventional therapy, minimally invasive surgical instruments and other medical equipment.

  2. Development goal

  The Binhai New Area targets at being built into a national bio-medicine industry base. By 2015, the scale of output value reached 80 billion yuan, accounting for about 3% of the industry of the New Area with average land output of 12 billion yuan per square km. By 2020, the output value will reach 160 billion yuan, accounting for about 4% of the industry of the New Area with average land output of 13 billion yuan per square km.

  3. Representative projects

  Project name

  Major products

  Introduction

GlaxoSmithKline (Tianjin) Co., Ltd.

Tablets, emulsions, liquid preparations and sterile eye drops

Ranking no.159 among the world's top 500 with annual profit of 8.9 billion US dollars

Danish Novo Nordisk (China) Pharmaceutical Co., Ltd.

Durable insulin injection devices, diabetes therapeutic products including the most advanced insulin delivery system products of human insulin, quick-acting insulin preparations, long-acting insulin analogs, hemostatic management, growth health hormones

Packaging about 78 million pieces/bottles of insulin and 3.4 million pieces of one-time insulin injection devices; producing 2.7 million pieces of durable insulin injection devices

  

 Danish Novozymes

R&D, manufacturing and sales of enzymic preparations and hyaluronic acid crude drug

Ranking top one in China with 40% of global market share and more than 4,000 valid patents

  French Servier (Tianjin) Pharmaceutical Co., Ltd.

It produces the first class, second class and fourth class new drugs for treating cardiovascular, endocrinology, neurology, depression, osteoporosis and other diseases. The drugs include Gliclazide, Acertil, Vasorel, Natrilix, Alvenor sustained release tablets, Tatinol, etc.

The largest private pharmaceutical group in France with annual production of 36 million boxes of drugs. It achieved the turnover of 180 million francs in China in 2000.

 Tianjin KingYork Group

 Corticosteroid crude drug

The largest corticosteroid crude drug producer in Asia with the revenue of 13.606 billion yuan, new profit and tax of 2.986 billion yuan and new foreign exchange of 269 million US dollars.

Tianjin Zhongwei Pharmaceutical Co., Ltd.

 Production of vitamin B1

Top one in Asia and top two in the world with nearly one third of global market share. It engages in vitamin B1 synthesis and efficient separation with an annual output of 1,500 tons

Tianjin Jianfeng Natural Product R&D Co., Ltd.

Anthocyanin, apple extract, resveratrol, zeaxanthin, lutein, black soybean extract, soybean isoflavone, etc.

It has the core technology for grape seed extraction.

 
Overview of Binhai
Overview of Binhai
Copyright 2008 Binhai New Area.All rights reserved. Reproduction in whole or in part without permission is prohibited.
Translation support service provider:All Star (Beijing) Translation Co., Ltd